ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1169

A Novel Pro-Inflammatory Signaling Pathway Regulated By Follistatin-Like Protein 1

Yury Chaly1, Anthony Marinov2, Yu Fu2, Brian Campfield2, John Kellum3, Bruce Hostager4, Daniel Bushnell5, Yudong Wang2, Jerry Vockley2 and Raphael Hirsch6, 1Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, IA, 2Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, 3University of Pittsburgh School of Medicine, Pittsburgh, PA, 4University of Iowa Carver College of Medicine, Iowa City, IA, 5Division of Pediatric Rheumatology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, 6Department of Pediatrics,, University of Iowa Carver College of Medicine, Iowa City, IA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: inflammasome activation, macrophages and monocytes

  • Tweet
  • Email
  • Print
Session Information

Title: Innate Immunity and Rheumatic Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: Follistatin-like protein 1 (FSTL1) is a secreted glycoprotein produced mainly by cells of the mesenchymal lineage. The function of FSTL1 is still unclear, but it appears to play roles in the regulation of cell proliferation, differentiation, and organ development. We have previously shown that FSTL1 is an important mediator in the pathogenesis of arthritis and other systemic autoimmune diseases, and that FSTL1 expression is induced in vitro by Toll-like receptor 4 signaling. The aim of the current study was to determine the molecular mechanism by which FSTL1 promotes inflammation. 

Methods: The level of FSTL1 in the sera of patients with sepsis was measured by ELISA. To further test the contribution of FSTL1 to inflammatory response in vivo, we utilized a model of endotoxin shock in FSTL1 null mice recently generated in our laboratory. Serum IL-1β  levels were determined by ELISA. FSTL1 binding to monocytes/macrophages and its intracellular trafficking were assessed by confocal microscopy. The expression of inflammasome components was evaluated by quantitative RT-PCR and Western blotting. To test whether FSTL1 plays a role in cellular energy production, we performed gene expression microarray analysis on ST2 stromal cells in which FSTL1 expression was knocked down using lentiviral short hairpin RNA.  Enzymatic assays and in situ gel staining were used to measure the activity of mitochondrial electron transport chain complexes. ATP determination in cell lysates was performed using a colorimetric assay. 

Results: We found that the sera of septic patients contained elevated levels of FSTL1 compared to healthy controls. In a mouse model of sepsis, animals deficient in FSTL-1 exhibited a significantly lower IL-1β response than did control mice. Our results indicate that FSTL1 may function to augment cellular responses to infectious organisms or various other noxious stimuli. We found that FSTL1 was able to gain access to the intracellular space of cells that do not normally express FSTL1, such as monocytes/macrophages, either via increased plasma membrane permeability or via an unidentified cell surface receptor. We found intracellular FSTL1 associated with mitochondria, where it enhanced ATP production.  FSTL1 also increased NLRP3 and pro-caspase-1 expression. Together, these promote activation of the NLRP3 inflammasome and secretion of IL-1β, one of the key regulators of inflammation.

Conclusion: Here, we demonstrate that FSTL1 has the ability to enhance the responses of monocytes/macrophages to inflammatory signals. The results reveal a novel mechanism by which FSTL1 acts in inflammation. Our work suggests that the neutralization of FSTL1 activity may be useful in the treatment of various inflammatory conditions.


Disclosure:

Y. Chaly,
None;

A. Marinov,

University of Pittsburgh,

9;

Y. Fu,
None;

B. Campfield,
None;

J. Kellum,
None;

B. Hostager,
None;

D. Bushnell,
None;

Y. Wang,
None;

J. Vockley,
None;

R. Hirsch,

University of Pittsburgh,

9.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-novel-pro-inflammatory-signaling-pathway-regulated-by-follistatin-like-protein-1/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology